The University of Chicago Header Logo

Connection

Daniel Arber to Tumor Suppressor Protein p53

Back to Details
This is a "connection" page, showing publications Daniel Arber has written about Tumor Suppressor Protein p53.
Daniel Arber
Connection Strength
2.984
Tumor Suppressor Protein p53
  1. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH. Am J Surg Pathol. 2018 07; 42(7):885-890.
    View in: PubMed
    Score: 0.451
  2. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
    View in: PubMed
    Score: 0.405
  3. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
    View in: PubMed
    Score: 0.190
  4. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
    View in: PubMed
    Score: 0.185
  5. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
    View in: PubMed
    Score: 0.185
  6. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
    View in: PubMed
    Score: 0.183
  7. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025 May 07; 15(1):88.
    View in: PubMed
    Score: 0.181
  8. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
    View in: PubMed
    Score: 0.179
  9. TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
    View in: PubMed
    Score: 0.179
  10. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.
    View in: PubMed
    Score: 0.178
  11. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 11 19; 14(1):202.
    View in: PubMed
    Score: 0.176
  12. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.170
  13. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019 02 11; 20(2):15.
    View in: PubMed
    Score: 0.118
  14. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015 May; 28(5):706-14.
    View in: PubMed
    Score: 0.088
  15. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
    View in: PubMed
    Score: 0.041
  16. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 04; 98(4):E76-E79.
    View in: PubMed
    Score: 0.039
  17. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.